Table 1. Association between CXCR7 expression and patients’ clinico-pathological features.
| CXCR7 expression | |||
|---|---|---|---|
| Clinico-pathological features | Negative | Positive | P |
| Age | 0.170 | ||
| <60 (n = 44) | 9 (.9.5) | 35 (37) | |
| ≥60 (n = 50) | 17 (18) | 33 (35) | |
| Gender | 1 | ||
| Male (n = 50) | 14 (15) | 36 (38) | |
| Female (n = 44) | 12 (13) | 32 (34) | |
| Bone marrow | 1 | ||
| Negative (n = 78) | 22 (24) | 56 (60) | |
| Positive (n = 15) | 4 (4) | 11 (12) | |
| Serum LDH | 0.819 | ||
| Normal (n = 44) | 13 (14) | 31 (33) | |
| High (n = 49) | 13 (14) | 36 (39) | |
| Stage | 0.162 | ||
| I-II (n = 43) | 15 (16) | 28 (31) | |
| III-IV (n = 48) | 10 (11) | 38 (42) | |
| ECOG performance status | 0.751 | ||
| 0–2 (n = 80) | 23 (24) | 57 (61) | |
| > 2 (n = 14) | 3 (3) | 11 (12) | |
| IPI | 0.052 | ||
| Low risk (n = 31) | 13 (14) | 18 (20) | |
| Low/intermediate (n = 24) | 5 (5.5) | 19 (21) | |
| High/intermediate (n = 21) | 1 (1) | 20 (22) | |
| High risk (n = 14) | 6 (7) | 8 (9) | |
| Chemotherapy | 1 | ||
| R-CHOP (n = 86) | 23 (25) | 63 (68) | |
| Others (n = 7) | 2 (2) | 5 (5) | |
| Recurrence | 0.607 | ||
| No (n = 69) | 18 (19) | 51 (54) | |
| Yes (n = 25) | 8 (8.5) | 17 (18) | |
| DLBCL subtype1 | 1 | ||
| Non-GCB (n = 44) | 13 (16) | 31 (38) | |
| GCB (n = 37) | 11 (13.5) | 26 (32) | |
| Condition | 0.044* | ||
| Alive (n = 75) | 17 (18) | 58 (62) | |
| Deceased (n = 19) | 9 (9) | 10 (11) | |
| CXCR4 | 0.819 | ||
| Negative (n = 46) | 12 (13) | 34 (36) | |
| Positive (n = 48) | 14 (15) | 34 (36) | |
n (%), patients for each studied variable. P values were calculated using Fisher’s exact test.
*P value ≤ 0.05. LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Group; IPI, International Prognostic Index.
1 Hans algorithm was used to determine the GCB/Non-GCB cases.
*P ≤ 0.05